Mayo Clinic
The purpose of this research is to identify the concentration of mannitol solution (a type of sugar alcohol) that will generate a range of symptoms in individuals without Disorders of Gut Brain Interaction (DGBI) to establish the normative range of responses to small bowel (SB) distension.
Inclusion Criteria: * No current gastrointestinal symptoms * No prior history of GI disorders, in particular DGBIs * Ability to provide informed consent * Ability to participate in study procedures * Absence of other diseases (structural or metabolic) which could interfere with interpretation of the study results * For females, must not be pregnant or lactating due to radiation exposure. * Stable doses of thyroid replacement, estrogen replacement, low-dose aspirin for cardioprotection, and birth control are permissible. Exclusion Criteria * Subjects on any medications that impact transit or…
Participants will ingest 500 mL of mannitol solution at 76 mOsm/L radiolabeled with 111Indium-DTPA during one testing visit.
Participants will ingest 500 mL of mannitol solution at 189 mOsm/L radiolabeled with 111Indium-DTPA during one testing visit.
Participants will ingest 500 mL of mannitol solution at 325 mOsm/L radiolabeled with 111Indium-DTPA during one testing visit.
Scintigraphy will be used to track gastric emptying, small bowel transit, and colonic filling of the radiolabeled mannitol solution during each testing visit.
Arctuva estimate
Verify or correct the compensation shown for this listing.